Antidepressants for irritable bowel syndrome

R E Clouse

Systematic reports of antidepressant use in irritable bowel syndrome (IBS) first appeared in the medical literature three decades ago. Recent meta-analyses of the cumulative controlled experience confirm the efficacy of antidepressants in IBS and other functional gastrointestinal disorders: only 3–4 patients require treatment to demonstrate a benefit over placebo—numbers indicating a solid treatment effect.1,2 Although many of the earlier reports would be considered scientifically flawed by today’s standards, the effects are consistent across studies. Odds ratios of treatment over placebo for primary study outcome, global (or syndromic) response, and pain exceeded 4.0 for each determination in one analysis, and the effect sizes of antidepressant treatment on continuous outcome measures were large.3 These observations in conjunction with reported open label experience and general clinical success have given antidepressants an important position in the therapeutic armamentarium for IBS.4

Most studies have employed tricyclic antidepressants (TCAs), medications that appear to have benefits not necessarily shared across the antidepressant class. Daily dosages of TCAs (25–125 mg/day) that are below the psychiatric range for antidepressant effect typically are effective in IBS, producing at least a moderate response in more than 85% of patients in open label use.5 With the TCAs, onset of action is rapid, effects appear sustained without tachyphylaxis, and the benefits are unrelated to change in measures of anxiety or depression—findings supporting a mechanism of action that is distinct from recognized psychiatric effects of the medications.6 Reported experience with contemporary antidepressants, including the selective serotonin reuptake inhibitors, is much less robust.6,7 These medications typically are used in full psychiatric dosages, onset of effect on IBS symptoms is not rapid, and the benefits may be related more to a reduction in associated anxiety or depressive symptoms and an indirect effect on IBS symptom reporting.8 The mechanistic difference between TCAs and contemporary antidepressants in IBS symptom management has not been completely determined, but clinical experience (including

---

Figure 1: An algorithm for the initiation of antidepressants in irritable bowel syndrome (IBS). *Combined treatment with a tricyclic antidepressant (TCA) and some contemporary antidepressants will reduce hepatic metabolism of the TCA wherein TCA levels must be monitored to avoid toxicity. From Clouse and Lustman.4

---

www.gutjnl.com
the benefits of combined treatment in some patients) favours important distinctions between antidepressant types.  

Treatment choices for IBS, in general, depend on symptom pattern (for example, constipation versus diarrhoea predominance) and severity (for example, mild to severe, as characterised by symptom intensity and functional impairment). As severity worsens, pain, other gastrointestinal discomfort (for example, bloating), and perceptions of bowel dysfunction often become dominant; the disorder is accompanied by more psychological distress, higher rates of comorbid psychiatric illness, and less responsiveness to usual treatment.  

Central regulatory control compared with gut factors may be more important in symptom production and perpetuation, and the pattern of bowel dysfunction becomes more important from the standpoint of side effects of therapy than in directing the intervention.  

These patients may be good candidates for antidepressant trials and have symptom severity that justifies the potential adverse effects seen with these agents. TCAs in particular produce unsatisfactory adverse effects in up to 40% of patients receiving open label treatment, such as sedation, other central nervous system complaints, and anticholinergic symptoms.  

When TCAs are used for neuropathic pain management, significant adverse effects compared with placebo are encountered with treatment of as few as 3–4 patients, and a major adverse effect attributable to treatment occurs in slightly fewer than 1 in 20 patients.  

Consequently, antidepressants appear well selected for patients with this off label indication who have at least moderately severe symptoms and in whom these adverse effects are acceptable.  

Adverse effects of TCAs in particular produce unsatisfactory adverse effects in up to 40% of patients receiving open label treatment, such as sedation, other central nervous system complaints, and anticholinergic symptoms.  

Active anxiety or depression symptoms interfere with treatment, particularly with low dose TCA regimens.  

Some psychological symptoms regress with successful IBS management; those that persist may require direct intervention for global improvement. Patients with many unexplained pain symptoms or syndromes, complicated medical histories beginning at an early age, and other features of somatisation disorder respond less well to antidepressants and often report adverse effects that overshadow drug benefits. These patients should be started at very low daily TCA dosages (for example, 10 mg/day) that are increased in similarly small increments. Thus the combination of symptom severity (or at least refractoriness to other interventions), presence of an active anxiety or affective disorder, and features of somatisation disorder weigh into the initial treatment decisions with antidepressants (fig 1).  

Although there is no uniformly accepted approach directing the use of antidepressants for IBS management, the algorithm outlined in fig 1 is successful for many patients.  

In the absence of an overt anxiety or affective disorder, TCAs may be preferred over contemporary antidepressants for suitable candidates. Secondary amine TCAs (nortriptyline, desipramine) are better tolerated by many patients than parent tertiary amines (amitriptyline, imipramine, doxepin) because of fewer anticholinergic, sedating anti-histaminic, and α-adrenergic adverse effects.  

Starting dosages of 10–25 mg at bedtime are recommended but daily dosages exceeding 30 mg/day are required for sustained benefit in most patients.  

The dosage can be escalated until sustained improvement is observed, adverse effects impact further increment, or the upper limit of conventional psychiatric dosing is reached. Not all patients achieve optimal response in the low dose range. Once a benefit is achieved, months of maintenance treatment may be required before the medication can be withdrawn without recurrence.  

Common long term adverse effects of TCAs that must be considered in the treatment approach include, among others, weight gain, hypertension, and sexual dysfunction. Clinicians using antidepressants in IBS management should be familiar with the adverse effects of these medications during short and long term use.

**REFERENCES**

Antidepressants for irritable bowel syndrome

R E Clouse

Gut 2003 52: 598-599
doi: 10.1136/gut.52.4.598

Updated information and services can be found at:
http://gut.bmj.com/content/52/4/598

These include:

References
This article cites 10 articles, 1 of which you can access for free at:
http://gut.bmj.com/content/52/4/598#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Irritable bowel syndrome (327)
Constipation (198)
Diarrhoea (663)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/